<?xml version="1.0" encoding="UTF-8"?>
<p id="Par59">Adalimumab (Humira) was the world’s best-selling drug in 2018. Adalimumab is a subcutaneously administered biological disease modifier used for the treatment of rheumatoid arthritis and other TNFα-mediated chronic debilitating diseases. It was originally launched by Abbvie in the United States after gaining approval from the US FDA in 2002. It has been shown that Adalimumab reduces the signs and symptoms of moderate to severe rheumatoid arthritis in adults, and it is also used to treat psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis [
 <xref ref-type="bibr" rid="CR47">47</xref>, 
 <xref ref-type="bibr" rid="CR48">48</xref>]. It may be used alone or in combination with disease-modifying anti-rheumatic drugs [
 <xref ref-type="bibr" rid="CR49">49</xref>].
</p>
